Immune effects of Lactobacillus casei Shirota in treated HIV-infected patients with poor CD4+ T cell recovery: a randomized trial.
HIV infection leads to depletion of intestinal CD4+ T cells, mucosal barrier dysfunction, increased gut permeability and microbial translocation even among patients on suppressive ART. Previous studies suggest probiotics may help restore intestinal function. In this double-blind, placebo-controlled pilot study, we enrolled HIV-infected patients on suppressive ART with poor CD4+ recovery to address the effect of daily oral use of Lactobacillus casei Shirota (LcS) on CD4+ T cell count and CD4/CD8 ratio at 6 and 12 weeks after treatment initiation; immune activation and intestinal microbiome composition were addressed as secondary outcomes. From Jan/2015 to Jul/2016, 48 patients were randomized (1:1) to active intervention or placebo. Groups had comparable demographic and clinical characteristics; only CD4+ T cell nadir was statistically different between groups. All participants were virologically-suppressed under ART. At week 6, the increment in CD4+ T cell count was 17 cells/mm3 (interquartile range [IQR] -33 to 74) in the active intervention arm and 4 cells/mm3 (IQR -43 to 51) in the placebo arm (p = 0.291); at week 12, the change in CD4+ T cell count was 8 cells/mm3 (IQR -30 to 70) in the active arm and 10 cells/mm3 (IQR -50 to 33) among participants allocated to placebo (p = 0.495). Median change in CD4/CD8 ratio at week 6 compared to baseline was 0 (IQR -0.04 to 0.05) in the active intervention arm and -0.01 in the placebo arm (IQR -0.06 to 0.03; p = 0.671). At week 12, the change in CD4/CD8 ratio was higher in the active product group compared to placebo (respectively 0.07 and 0.01), but this difference failed to reach statistical significance (p = 0.171). We found no significant effects of LcS on immune activation markers, CD4+ and CD8+ subpopulations, sCD14 levels or NK cells at week 12. Finally, we found no statistically significant differences between groups in the change of enteric microbiome at week 12. In this pilot study, we found no statistically significant effect of LcS probiotic on CD4+ T cell counts, CD4/CD8 ratio, immune activation or intestinal microbiome among HIV-infected patients on suppressive ART with poor CD4+ recovery.